Nightstar Therapeutics, a UK biotech developing gene therapies for rare retinal diseases, raised $75 million by offering 5.4 million shares at $14, at the midpoint of $13 to $15 targeted range. Nightstar Therapeutics plans to list on the Nasdaq under the symbol NITE. Jefferies, Leerink Partners and BMO Capital Markets acted as lead managers on the deal.
